A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)

Study identifier:ACE-ST-209

ClinicalTrials.gov identifier:NCT02586857

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)

Medical condition

Glioblastoma Multiforme

Phase

Phase 1/2

Healthy volunteers

No

Study drug

ACP-196

Sex

All

Actual Enrollment

24

Study type

Interventional

Age

n/a - n/a

Date

Study Start Date: 25 Jan 2016
Primary Completion Date: 26 Jun 2020
Estimated Study Completion Date: 31 Dec 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria